BPC November 01 update

Biotech stock catalysts for the week ahead; Biotech week in Review

Weekly watchlist

This week’s watch list looks at potential catalysts slated for the upcoming week, with much focus on the Society for Immunotherapy of Cancer's (SITC) Annual Meeting from November 7-10. Full regular and late-breaking abstracts will be released to the public on November 5 at 8am EST.

First, let’s review a selection of price-moving events from the week that was.

Agile Therapeutics, Inc. (NASDAQ:AGRX) shares closed Thursday up 224% to $1.20 following Wednesday’s FDA Advisory Committee meeting which delivered a 14 to 1 vote (1 abstention) supporting approval of the New Drug Application (NDA) for its contraceptive patch, Twirla. The surge reversed the move earlier in the week, where shares slumped following the release of briefing documents on Monday for the meeting, falling 67% from $1.11 to $0.37 in the two days leading up to the panel. The PDUFA date for a final decision by the FDA is November 16, 2019.

BeiGene, Ltd. (NASDAQ:BGNE) shares closed Friday up 37% to $189.56 following news released late-Thursday of a collaboration with Amgen (NASDAQ: AMGN) for the commercialization and development in China of Amgen's oncology drugs. Amgen will purchase a 20.5% stake in BeiGene for approximately $2.7b in cash.

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) shares closed the week down 19% to $9.94 following a negative vote from an Advisory Committee reviewing its marketed treatment Makena for pre-term births. The panel voted 9-7 in favor of recommending the withdrawal of Makena from the market, following a post-approval trial that showed the treatment not to be effective. Makena was originally approved in 2011.

Mirati Therapeutics, Inc. (NASDAQ: MRTX) shares closed the week up 23% to $100.04 following data released Monday from its Phase 1/2 trial evaluating its KRAS inhibitor, MRTX849, in patients with solid tumors expressing KRAS G12C mutations. Across all dose levels, three of six patients with non-small cell lung cancer (NSCLC) and one of four patients with colorectal cancer (CRC) achieved a partial response.

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) shares slumped to close the week down 78% to $2.45 following news that it did not meet the primary endpoints in two Phase 2 trials, of praliciguat, in heart failure with preserved ejection fraction (HFpEF) and in diabetic nephropathy, respectively.

Iveric bio, Inc. (NASDAQ: ISEE) shares closed the week up 309% to $3.80. The company announce its Phase 2b trial of Zimura met the primary endpoint in reducing the rate of geographic atrophy (GA) growth in patients with dry age-related macular degeneration (AMD).

Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX) announced that its Phase 3 CMS-001 trial evaluating amifampridine phosphate for the symptomatic treatment of genetically confirmed Congenital Myasthenic Syndromes (CMS), did not meet its primary endpoint. Shares closed the week down 14% to $4.81.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) announced a research collaboration and licensing agreement with Roche (OTCQX: RHHBY) to develop therapies for the treatment of chronic hepatitis B virus (HBV) infection using Dicerna’s RNAi platform technology. Dicerna will receive $200m in an initial upfront payment. Shares closed Thursday up 5% to $16.49. Arbutus Biopharma Corporation (Nasdaq: ABUS) saw its shares climb 60% to $1.42 in sympathy to the move, with the company also targeting HBV using RNA.


Selection of 15 top revenue earning companies reporting 3Q earnings during the week of November 4:





Other biotech events to watch over next week:

Drug Stage Catalyst Market Cap

AGEN – Agenus Inc.
AGEN2034 (anti-PD-1)
Cervical cancer

Phase 1/2 Subset analysis of Phase I dose escalation trial presented at SITC November 8, 2019.
$515.1 million

ALKS – Alkermes plc
Solid tumors

Phase 1 Phase 1/2 data at SITC November 2019 - 8/14 SD for monotherapy, 12/18 for combo (incl. 2 PRs).
$2.8 billion

ASMB – Assembly Biosciences Inc.
Hepatitis B virus (HBV)

Phase 2a Phase 2a data presented at AASLD November 11, 2019.
$555.2 million

CRVS – Corvus Pharmaceuticals Inc.
Solid tumors

Phase 1b Phase 1/1b updated at SITC November 8, 2019 noted tumor regression in 4/9 patients receiving 6 mg/kg or higher.
$184.6 million

ELOX – Eloxx Pharmaceuticals Inc.

Phase 2 Phase 2 data released January 14, 2020.
$157.2 million

FGEN – FibroGen Inc
Anaemia in Chronic Kidney Disease

NDA Filing NDA filing announced December 23, 2019.
$3.7 billion

IOVA – Iovance Biotherapeutics Inc.
LN-144 - lifileucel
Refractory metastatic melanoma

Phase 2 Phase 2 pivotal cohort completion of enrolment announced January 15, 2020 with top-line data due 2020. BLA filing late-2020.
$2.8 billion

NXTC – NextCure Inc.
Solid tumors

Phase 1/2 Phase 2 part to be completed 4Q 2020.
$1.2 billion

PIRS – Pieris Pharmaceuticals Inc.
HER2-positive solid tumors

Phase 1/2 Phase 1 complete data due 2020.
$215.6 million

SNY – Sanofi
Soild tumors

Phase 1/2 Phase 1 biomarker data from first cohort to be presented 1H 2020.
$121.8 billion

SURF – Surface Oncology Inc.
Hematologic malignancies, solid tumors

Phase 1 Phase 1 data presented at SITC meeting November 9, 2019.
$74.7 million